Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.51 |
| ▸ | P2RY12 | Q9H244 | 2/20 | 0.51 |
| ▸ | BMPR1B | O00238 | 1/20 | 0.49 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.48 |
| ▸ | P2RY2 | P41231 | 1/20 | 0.48 |
| ▸ | P2RY1 | P47900 | 1/20 | 0.48 |
| ▸ | P2RY6 | Q15077 | 1/20 | 0.48 |
| ▸ | DNPH1 | O43598 | 1/20 | 0.47 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16940281 | 1.00 | PRMT6 (0.51) | PRMT6P2RY12BMPR1BADORA1P2RY2 | |
| SCHEMBL19399423 | 1.00 | PRMT6 (0.51) | PRMT6P2RY12BMPR1BADORA1P2RY2 | |
| SCHEMBL7064875 | 0.93 | ADORA1 (0.56) | ADORA1ADORA3 | |
| SCHEMBL7064871 | 0.93 | ADORA1 (0.56) | ADORA1ADORA3 | |
| SCHEMBL19407591 | 0.93 | ADORA1 (0.56) | ADORA1ADORA3 | |
| SCHEMBL38653713 | 0.93 | ADORA1 (0.56) | ADORA1ADORA3 | |
| SCHEMBL25765124 | 0.92 | MEN1 (0.54) | PRMT6P2RY12BMPR1BADORA1P2RY2 | |
| SCHEMBL26553799 | 0.92 | MEN1 (0.54) | PRMT6P2RY12BMPR1BADORA1P2RY2 | |
| SCHEMBL20149845 | 0.92 | PRMT6 (0.51) | PRMT6P2RY12BMPR1BADORA1P2RY2 | |
| SCHEMBL20149848 | 0.91 | PRMT6 (0.52) | PRMT6P2RY12BMPR1BADORA1P2RY2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230203078-A1 | SYNTHESIS OF 3'N NUCLEOSIDES THROUGH OXIME INTERMEDIATES AND RELATED COMPOUNDS | Janssen Biopharma, Inc. | 2023-06-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230203078-A1 | SYNTHESIS OF 3'N NUCLEOSIDES THROUGH OXIME INTERMEDIATES AND RELATED COMPOUNDS | NT5C3B, PNP, NME1 | PRMT6 289/4885P2RY12 2788/4885BMPR1B 1373/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.